When pain has lasted for months, it is understandable to start looking beyond the usual options.
Maybe exercise has helped, but not enough. Perhaps medication only provides temporary relief. You may have been told that surgery is eventually possible, but you are not ready to take that step.
This is often when people begin hearing about platelet-rich plasma, commonly called PRP, and other treatments described as regenerative medicine.
Unfortunately, the conversation online tends to fall into two extremes. One side presents these treatments as miracle cures. The other dismisses all of them as hype.
The truth is more useful—and more nuanced.
Some regenerative treatments show promise for selected patients and conditions. Others still have limited, inconsistent, or developing evidence. The right question is not simply, “Does regenerative medicine work?”
The better question is, “What does the research say about this specific treatment for my specific condition?”
PRP begins with a sample of your own blood.
The blood is processed to separate and concentrate a portion of the plasma containing platelets. The resulting preparation is then injected into the targeted area.
Platelets are best known for their role in clotting, but they also contain signaling proteins involved in the body’s healing and inflammatory processes. The idea behind PRP is to deliver a concentrated amount of those components to an injured or painful area.
Because PRP preparations can differ in platelet concentration, white blood cell content, processing method, injection schedule, and other characteristics, “PRP” is not one perfectly standardized product. Research published in 2025 described PRP as a spectrum of preparations and identified inconsistent reporting and a lack of standardization as continuing challenges in the field.
That variation helps explain why two people may receive treatments both called PRP but have different protocols and different outcomes.
Knee osteoarthritis is one of the most extensively studied orthopedic uses of PRP.
A 2024 review that examined 39 systematic reviews and meta-analyses found that PRP generally improved knee osteoarthritis pain, function, stiffness, and quality of life during follow-up periods of up to 12 months. The authors also emphasized the need for stronger information about longer-term outcomes.
A separate meta-analysis of 18 randomized trials found clinically meaningful improvements in pain and function compared with placebo at several follow-up points. It also suggested that the composition and platelet concentration of the preparation may influence results.
More recently, a 2026 randomized trial studied 90 adults with advanced knee osteoarthritis who were awaiting joint-replacement surgery. Eighty-two completed the six-month follow-up. In that study, two PRP injections produced greater improvements in pain, stiffness, and function than corticosteroid injection or an oral anti-inflammatory medication. The adverse events reported in the PRP group were mild and temporary.
That is encouraging, but one positive trial does not mean every person with knee pain will respond in the same way. It also does not establish that PRP permanently repairs cartilage or eliminates the possibility of future surgery.
Research reviews do not all reach the same level of confidence.
A 2025 critical evaluation of 17 systematic reviews comparing PRP with hyaluronic acid found that results often favored PRP, but the authors rated the overall methodological quality of the reviews as extremely low and found a high risk of bias.
This does not mean the treatment has no value. It means the evidence should be discussed honestly.
PRP may help certain patients, particularly with some presentations of knee osteoarthritis. However, the ideal preparation, number of injections, timing, patient characteristics, and long-term effects are still being studied.
Most importantly, results for one condition should not automatically be applied to another.
For example, a 2026 meta-analysis of four randomized trials involving 337 patients found no significant advantage for PRP over placebo for Achilles tendinopathy at three or six months.
That is why the diagnosis comes before the injection.
The phrase “regenerative medicine” includes several different types of treatments. PRP is derived from a patient’s blood. Cell-based products may involve adipose tissue, bone marrow, umbilical tissue, or other sources.
These products should not be presented as interchangeable.
inMotionRx’s regenerative medicine page currently lists PRP, MiniStem—which combines PRP with adipose-derived cells—and MaxxStem—which combines PRP, adipose-derived components, and bone marrow.
Because the ingredients, processing, evidence, risks, and regulatory requirements differ, patients deserve a clear explanation of exactly what is being proposed.
The FDA states that stem-cell and adipose-derived regenerative products have not been approved to treat orthopedic conditions such as osteoarthritis, tendinitis, back pain, knee pain, hip pain, neck pain, or shoulder pain. The FDA encourages patients to ask how a proposed product is regulated, whether approval is required, and whether it has been approved for the intended use.
The purpose of that information is not to create fear. It is to make informed consent meaningful.
A responsible conversation should clearly separate what is established, what is promising, and what remains uncertain.
Before agreeing to any regenerative procedure, ask:
A provider should welcome these questions.
Even when an injection reduces pain, the body may still need help rebuilding capacity.
A procedure cannot independently restore quadriceps strength, improve balance, increase tendon tolerance, correct a sudden spike in training volume, or prepare the body for the demands of work and sport.
That is where physical therapy remains important.
Exercise is still recommended across major knee osteoarthritis guidelines, and the 2024 Cochrane review found that exercise probably improves short-term pain and physical function, although individual responses vary.
For some patients, the best plan may involve rehabilitation alone. For others, a medical procedure may help create a window in which movement and strengthening become more manageable.
The plan should be based on the patient—not on selling a particular procedure.
Regenerative medicine is an evolving area of healthcare. There is meaningful research behind some applications, significant uncertainty around others, and no treatment that guarantees the same result for everyone.
At inMotionRx, patients have access to both movement-based rehabilitation and physician-directed regenerative consultations. That creates an opportunity to look at the full picture: diagnosis, activity goals, strength, mobility, previous treatment, medical history, and realistic expectations.
The goal should never be to chase the newest treatment simply because it is new.
The goal is to choose the most appropriate path for your body, your condition, and the life you want to return to.
Considering PRP or another regenerative option?
Schedule a consultation with inMotionRx to discuss the evidence, your diagnosis, and the next appropriate step.
